【摘要】 近年来吸入一氧化氮(NO)的新应用指征研究集中在早产儿慢性肺病(CLD)防治的有效性方面。临床大样本单中心或多中心研究揭示其对降低CLD发生,甚至减少颅内损害也有潜在影响,在出生体重>1000g的早产儿相对更明显。在多数研究中所采用的吸入NO剂量为5×10-6容量体积以下,1～2周连续吸入治疗。更多的安全性研究将依据长期随访结果,目前临床尚不作为常规治疗,但是对于比较难治愈的CLD,或有呼吸机相关性肺炎风险时,可以考虑将该治疗方法作为研究性使用。更多还原

【Abstract】 One of the new indications of inhaled nitric oxide(NO) now is focused on efficacy of prevention and treatment of chronic lung disease(CLD) in prematurity.Results from large-sample randomized trials of single or multicenter based studies revealed that NO therapy reduced incidence of CLD as well as brain damage,especially in those with birth weight above 1000 g.The dosage of inhaled NO in most of the studies was below 5 parts per million,and usually supplied continuously for 1-2 weeks.As more evidence of safety is required based on follow-up studies,this therapy is not recommended for routine use.However,in patients with CLD and ventilator dependence,or patients at high risk of ventilator-associated pneumonia,NO therapy can be considered for investigational use only.更多还原